• About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

o2h-ventures

  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

Don’t invest unless you’re prepared to lose all your money invested. This is a high risk investment. You could lose all the money you invest and are unlikely to be protected if something goes wrong. Take 2 mins to learn more

o2h Ventures makes an investment into Xploro from “the o2h human health SEIS fund”
o2h Ventures makes an investment into Xploro from “the o2h human health SEIS fund”
Feb 16 2022

Cambridge, UK, 16 Feb 2022: o2h Ventures is pleased to announce an SEIS investment into Xploro®, a Manchester based company using augmented reality, gameplay, and artificial intelligence to deliver health information to young patients. 

Xploro reassures patients by clarifying what the upcoming procedure will accomplish, and assists in minimising procedural anxiety by enhancing health literacy and awareness about the treatment. Xploro has one of the highest ORCHA scores (Orcha seeks out the most popular digital health solutions and reviews them for compliance and best practice.)

Artificial Intelligence’s growing influence and role in revolutionising the healthcare business cannot be overlooked while discussing medical trends. Additionally, when AI is used to power AR(Augmented reality), the impact of AI opportunities becomes much larger and can positively affect society’s health system. 

o2h Ventures has a track record of supporting and investing in some of the UK’s most innovative early-stage biotech firms and this is o2h Ventures’ fourth investment into digital therapeutics.

Sunil Shah, CEO at o2h Ventures said: “Dom has amazing insight and passion to provide support for these young patients.  He has first hand experience for the needs and thus we are excited to support this investment from our newly launched SEIS fund.”

Dom Raban, CEO at Xploro® said: “This investment from o2h Ventures supports Xploro in our mission to help children during treatment for a serious illness. It means we can continue to develop the platform and innovate in new ways and, in turn, offer its benefits to even more families. o2h were a great fit for us with their proven track record in Life Sciences and enthusiasm for what we’re doing”.

About Xploro®

Founded in 2019, Xploro® is an award winning and clinically verified health information mobile application that leverages augmented reality, games, and artificial intelligence to give health information to young patients in a way that empowers, engages, and informs them while having fun by putting health information in the hands by using language they understand and interaction paradigms that the patients are familiar with.

Xploro aims to reduce patients’ stress and anxiety and improve their clinical outcomes by reducing the fear associated with procedures and aim to reduce repeat procedures and shorten treatment times by enhancing  child health literacy. They provide the foundations for a generation of patients better able to self-manage their healthcare.

For more information, please see – https://xploro.health/

About o2h Ventures

The o2h Ventures ‘Human Health’ SEIS and EIS funds make tax-efficient investments in Pre-Seed and Seed stage companies that address human disease: we fund the development of novel therapeutic treatments; we help build new services and tools offerings throughout the biotech ecosystem, and we spur the creation of software & artificial intelligence that will change healthcare.

The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h Ventures operates from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.

For more information or to invest in the fund, please visit www.o2hventures.com 

 

Media Contact:

Ayushi Vijayvargiya

Marketing Executive

ayushi.vijayvargiya@o2h.com

 

Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
  • youtube
o2h-ventures
recent press releases
  • o2h Ventures backed Small Pharma unveils positive phaseIIa results Exciting news as o2h Ventures’ portfolio company Small Pharma, unveils positive top-line results of their Phase IIa clinical trial for treating MDD 31 January, 2023
  • Kuano wins Innovate UK grant o2h Ventures backed Kuano wins Innovate UK funding for designing the next generation of cancer drugs 18 January, 2023
  • o2h Ventures funds o2h Ventures invests in Qkine – once again… 22 December, 2022
o2h-ventures
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years.
Useful Links
  • About Us
  • Blog
  • Documents Centre
  • Contact Us
  • Team
News
  • Oct 2022, o2h Ventures Fund Newsletter, KI EIS Closing, EISA events
  • Aug-Sept 2022, o2h Ventures Fund Newsletter, fifty percent of our companies led by female and more portfolio updates
  • July 2022, o2h Ventures Fund Newsletter, Deals executed in Alevin Therapeutics, Neurofenix, Five Alarm Bio
Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
© 2023 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us
o2h ventures Limited is regulated and authorised by the Financial Conduct Authority (FRN 812245). Capital at risk, only suitable for high net worth and sophisticated investors

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

1 – You could lose all the money you invest

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)